For more information call (888) LUHS-888.
Ellen R. Gaynor
Patients who are at least18 years of age with the following criteria may be eligible:
Histologically or cytologically proven diagnosis of adenocarcinoma of the prostate. All patients must have distant metastatic (brain metastases are not eligible).
PSA = 2 ng/mL obtained within 90 days prior to initiation of androgen deprivation therapy for early induction or prior to registration for late induction
Participants may not have Grade III/IV cardiac disease or uncontrolled hypertension
Participants must have adequate hepatic, renal and hematologic function
Participants must have a Zubrod performance status of 0 - 2
The purpose of this study is to find out what effects (good and/or bad) there are to adding the new investigational drug TAK-700 (also called orteronel) to standard hormone therapy, which is used to treat prostate cancer as compared with the standard of hormone therapy alone. The combination of TAK-700 and standard hormone therapy is considered experimental.